Poxel: preliminary results for Twymeeg study

(CercleFinance.com) - Poxel and its Japanese partner Sumitomo Pharma announce preliminary results from a post-marketing clinical study, TWINKLE, evaluating Twymeeg in Japanese patients with type 2 diabetes and renal failure.


According to the biopharmaceutical company, the safety and tolerability profile was in line with previous clinical studies in the general population with type 2 diabetes, with most adverse events being of mild to moderate severity.

Based on these results, Sumitomo Pharma plans to hold discussions with regulatory authorities in Japan, with a view to revising the drug's package insert in its fiscal year 2024 for patients with renal failure.

Copyright (c) 2024 CercleFinance.com. All rights reserved.